OTC · Health care

Vaccinex, Inc. (VCNX)

Vaccinex, Inc. reported revenue of $601K in fiscal 2024, up 5.4% from a year earlier. It posted a net loss of $18.6M. In fiscal 2024 capital spending exceeded operating cash flow by $16.2M. At December 31, 2024 it held $1.1M in cash against $25K of debt. Its latest periodic report to the SEC is the annual report (10-K) filed on April 15, 2025.

Watch VCNX in 60 seconds

Price

$1.00

+33.10% on the day · September 28, 2026

52-week range $0.31 to $1.50

Market cap

$2.7M

Revenue (FY2024)

$601K

+5.4% year on year

Net margin

-3,100.5%

What Vaccinex, Inc. does

Vaccinex, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker VCNX.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2024	$601K	-$18.7M	-$18.6M	-$8.88	-$16.2M
2023	$570K	-$22.9M	-$20.3M	-$43.68	-$21.4M
2022	$275K	-$19.9M	-$19.8M	-$98.05	-$19.2M
2021	$900K	-$22.5M	-$22.4M	-$162.72	-$25.3M
2020	$625K	-$28.3M	-$28.9M	-$321.27	-$28.9M
2019	$523K	-$32M	-$31.9M	-$515.28	-$30.8M

Full financial statements: income, balance sheet and cash flow

Where VCNX ranks in Health care

Revenue$601K

#666 of 742 in Health care · Bottom 10%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Vaccinex, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

April 15, 2025
Annual report 10-K · period to December 31, 2024Revenue rose 5.4% to $601K versus the prior year; diluted EPS -$8.88 versus -$43.68.
April 1, 2025
Late annual report notice NT 10-K
March 27, 2025
Deregistration 15-12G
March 25, 2025
Form POS AM filing POS AM
March 25, 2025
Form POS AM filing POS AM
March 25, 2025
Form POS AM filing POS AM
March 25, 2025
Form POS AM filing POS AM
March 25, 2025
Form POS AM filing POS AM
March 25, 2025
Form POS AM filing POS AM
March 25, 2025
Form POS AM filing POS AM

Recent insider filings (Forms 3, 4 and 144): 10, the latest on November 18, 2024. Insider transactions on SEC

All filings on SEC EDGAR

Questions about VCNX

What does Vaccinex, Inc. do?

Vaccinex, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker VCNX.

Is Vaccinex, Inc. profitable?

No. In fiscal 2024 it reported a net loss of $18.6M on revenue of $601K.

How much revenue does Vaccinex, Inc. make?

In fiscal 2024 Vaccinex, Inc. reported revenue of $601K. That is 5.4% more than a year earlier.

When did Vaccinex, Inc. last report?

Its most recent periodic report is the annual report (10-K) filed on April 15, 2025. It covers the period to December 31, 2024.

Similar companies

TAK

Takeda Pharmaceutical Co Ltd

Compare VCNX with

Compare VCNX with any company

Follow VCNX

Get an email when Vaccinex, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow VCNX: get an email when it files

Where the numbers come from

Financial figures are the values Vaccinex, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.